Loading…
Lobbying Income
$38.7M
Filings
866
Unique Clients
23
Active Period
2003–2020
Registrant-reported income from clients on LDA filings
Largest clients by registrant-reported income
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Medicare Negotiation and Competitive Licensing Act of 2019
2019 · first_quarter · Client: PHRMA
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1046
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1503
Further Extension of Continuing Appropriations Act, 2021
2019 · first_quarter · Client: PHRMA
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1520
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2021
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2113
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
2019 · first_quarter · Client: PHRMA
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 269
Prescription Drug Price Relief Act of 2019
2019 · first_quarter · Client: PHRMA
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 465
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 938
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 965
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing S. 102/H.R. 465, Prescription Drug Price Relief Act of 2019, provisions relating to the pricing of prescription drug prices and intellectual property rights. H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $50,000
Matched citations: S. 102
Medicare Negotiation and Competitive Licensing Act of 2019
2019 · first_quarter · Client: MERCK & CO., INC.
H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1046
Orange Book Transparency Act of 2020
2019 · first_quarter · Client: MERCK & CO., INC.
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1503
Further Extension of Continuing Appropriations Act, 2021
2019 · first_quarter · Client: MERCK & CO., INC.
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1520
Investing for the People Act of 2019
2019 · first_quarter · Client: MERCK & CO., INC.
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 2021
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 2113
Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019
2019 · first_quarter · Client: MERCK & CO., INC.
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 269
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 938
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements. H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, provisions relating to patent exclusivity. H.R. 1520, the Purple Book Continuity Act of 2019, provisions that would codify publication of the patents of approved biological products in the Purple Book in a similar format and with similar requirements to the Orange Book H.R. 1503, the Orange Book Transparency Act of 2019, provisions to ensure that the Orange Book is accurate and up-to-date H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 269, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019, vaccines and other various provisions.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 965
Medicare Negotiation and Competitive Licensing Act of 2019
2019 · first_quarter · Client: AMGEN
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1046
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2021
H.R. 2021, Investing for the People Act of 2019, budget legislation, potential provisions relating to prescription drug pricing, reporting and oversight. H.R. 2113, the Prescription Drug Sunshine, Transparency, Accountability and Reporting Act or Prescription Drug STAR Act, provisions relating to prescription drug pricing, reporting and oversight requirements.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 2113
H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, provisions that would establish a process by which generic manufacturers could obtain sufficient quantities of brand drug samples for testing H.R. 1046, Medicare Negotiation and Competitive Licensing Act of 2019, provisions relating to prescription drug pricing and intellectual property rights.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 965
Setting Every Community Up for Retirement Enhancement Act of 2019
2019 · first_quarter · Client: PRUDENTIAL FINANCIAL INC
H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. Legislation to enhance retirement plan options
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1994
Retirement Enhancement and Savings Act of 2018
2019 · first_quarter · Client: PRINCIPAL FINANCIAL GROUP
H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. H.R.5282/S.2526, Retirement Enhancement and Savings Act, provisions encouraging workers to save more for retirement, small employer retirement plan coverage, worker participation and education, and facilitates guaranteed lifetime income in retirement.
Client expense: — · Firm income: $30,000
Matched citations: H.R.5282
Setting Every Community Up for Retirement Enhancement Act of 2019
2019 · first_quarter · Client: PRINCIPAL FINANCIAL GROUP
H.R. 1994, the Setting Every Community Up for Retirement Enhancement (SECURE) Act of 2019, provisions to expand opportunities to increase retirement savings and improve the portability of lifetime income options from one plan to another. H.R.5282/S.2526, Retirement Enhancement and Savings Act, provisions encouraging workers to save more for retirement, small employer retirement plan coverage, worker participation and education, and facilitates guaranteed lifetime income in retirement.
Client expense: — · Firm income: $30,000
Matched citations: H.R. 1994
Source: Senate LDA